- Home
- ASA vs KROS Comparison
ASA vs KROS Comparison
Compare ASA & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASA
- KROS
- Stock Information
- Founded
- ASA 1958
- KROS 2015
- Country
- ASA United States
- KROS United States
- Employees
- ASA N/A
- KROS N/A
- Industry
- ASA Precious Metals
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- ASA Industrials
- KROS Health Care
- Exchange
- ASA Nasdaq
- KROS Nasdaq
- Market Cap
- ASA 697.1M
- KROS 565.0M
- IPO Year
- ASA N/A
- KROS 2020
- Fundamental
- Price
- ASA $52.95
- KROS $13.74
- Analyst Decision
- ASA
- KROS Buy
- Analyst Count
- ASA 0
- KROS 14
- Target Price
- ASA N/A
- KROS $20.56
- AVG Volume (30 Days)
- ASA 154.4K
- KROS 773.9K
- Earning Date
- ASA 10-28-2025
- KROS 11-05-2025
- Dividend Yield
- ASA 0.12%
- KROS N/A
- EPS Growth
- ASA 335.96
- KROS N/A
- EPS
- ASA 19.90
- KROS 0.47
- Revenue
- ASA $3,982,215.00
- KROS $232,844,000.00
- Revenue This Year
- ASA N/A
- KROS $6,657.47
- Revenue Next Year
- ASA N/A
- KROS N/A
- P/E Ratio
- ASA $2.62
- KROS $29.52
- Revenue Growth
- ASA 99.75
- KROS 85820.30
- 52 Week Low
- ASA $19.37
- KROS $9.12
- 52 Week High
- ASA $53.76
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- ASA 81.83
- KROS 31.18
- Support Level
- ASA $46.18
- KROS $15.50
- Resistance Level
- ASA $49.14
- KROS $16.44
- Average True Range (ATR)
- ASA 1.81
- KROS 0.72
- MACD
- ASA 0.40
- KROS -0.23
- Stochastic Oscillator
- ASA 94.02
- KROS 2.92
About ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.